双重作用的组蛋白去乙酰化酶-拓扑异构酶 I 抑制剂。
Dual-acting histone deacetylase-topoisomerase I inhibitors.
机构信息
School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA.
出版信息
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3283-7. doi: 10.1016/j.bmcl.2013.03.108. Epub 2013 Apr 4.
Abstract
Current chemotherapy regimens are comprised mostly of single-target drugs which are often plagued by toxic side effects and resistance development. A pharmacological strategy for circumventing these drawbacks could involve designing multivalent ligands that can modulate multiple targets while avoiding the toxicity of a single-targeted agent. Two attractive targets, histone deacetylase (HDAC) and topoisomerase I (Topo I), are cellular modulators that can broadly arrest cancer proliferation through a range of downstream effects. Both are clinically validated targets with multiple inhibitors in therapeutic use. We describe herein the design and synthesis of dual-acting histone deacetylase-topoisomerase I inhibitors. We also show that these dual-acting agents retain activity against HDAC and Topo I, and potently arrest cancer proliferation.
摘要
目前的化疗方案主要由单靶点药物组成，这些药物常常受到毒性副作用和耐药性发展的困扰。一种规避这些缺点的药理学策略可能涉及设计多价配体，这些配体可以调节多个靶点，同时避免单靶点药物的毒性。组蛋白去乙酰化酶（HDAC）和拓扑异构酶 I（Topo I）是两种有吸引力的靶点，它们是细胞调节剂，可以通过一系列下游效应广泛阻止癌细胞增殖。这两个靶点都是经过临床验证的靶点，有多种抑制剂在治疗中使用。本文描述了双作用组蛋白去乙酰化酶-拓扑异构酶 I 抑制剂的设计和合成。我们还表明，这些双作用试剂保留了对 HDAC 和 Topo I 的活性，并能有效地抑制癌症的增殖。
相似文献
1
Dual-acting histone deacetylase-topoisomerase I inhibitors.双重作用的组蛋白去乙酰化酶-拓扑异构酶 I 抑制剂。
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3283-7. doi: 10.1016/j.bmcl.2013.03.108. Epub 2013 Apr 4.
2
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.一种新型小分子伏立诺他和 DACA 的杂合体通过双重抑制组蛋白去乙酰化酶和拓扑异构酶 I 显示出对人激素难治性转移性前列腺癌的抗癌活性。
Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.
3
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.喜树碱-沙马普林A杂合物作为拓扑异构酶I和组蛋白去乙酰化酶双重作用抑制剂
Eur J Med Chem. 2018 Jan 1;143:2005-2014. doi: 10.1016/j.ejmech.2017.11.021. Epub 2017 Nov 8.
4
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.新型双功能抑制剂双重靶向组蛋白去乙酰化酶和拓扑异构酶 II。
J Med Chem. 2012 Feb 23;55(4):1465-77. doi: 10.1021/jm200799p. Epub 2012 Feb 13.
5
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.设计、合成并评估吖啶羟肟酸衍生物作为双重 Topo 和 HDAC 抑制剂的抗癌活性。
Bioorg Med Chem. 2018 Aug 7;26(14):3958-3966. doi: 10.1016/j.bmc.2018.06.016. Epub 2018 Jun 20.
6
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.杂合拓扑异构酶 I 和组蛋白去乙酰化酶抑制剂作为双重作用的抗癌剂。
PLoS One. 2018 Oct 9;13(10):e0205018. doi: 10.1371/journal.pone.0205018. eCollection 2018.
7
3-Arylisoquinolines as novel topoisomerase I inhibitors.3-芳基异喹啉类作为新型拓扑异构酶 I 抑制剂。
Bioorg Med Chem. 2011 Jan 15;19(2):724-34. doi: 10.1016/j.bmc.2010.10.057. Epub 2010 Nov 2.
8
Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.组蛋白去乙酰化酶和 DNA 拓扑异构酶 II 靶向抑制剂的合成与生物评价。
Bioorg Med Chem. 2018 May 1;26(8):1920-1928. doi: 10.1016/j.bmc.2018.02.042. Epub 2018 Feb 27.
9
Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.黑色素瘤靶向组蛋白去乙酰化酶抑制剂的抗增殖活性的设计、合成与评价
Bioorg Med Chem Lett. 2017 Feb 15;27(4):744-749. doi: 10.1016/j.bmcl.2017.01.044. Epub 2017 Jan 17.
10
Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.7-烯丙基同型喜树碱的合成及生物评价作为有效的拓扑异构酶 I 抑制剂。
Chem Biodivers. 2012 Jun;9(6):1084-94. doi: 10.1002/cbdv.201100195.
引用本文的文献
1
Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors.组蛋白去乙酰化酶/微管蛋白双靶点抑制剂开发的最新进展
Pharmaceuticals (Basel). 2025 Feb 27;18(3):341. doi: 10.3390/ph18030341.
2
MolBiC: the cell-based landscape illustrating molecular bioactivities.MolBiC：基于细胞的展现分子生物活性的图谱
Nucleic Acids Res. 2025 Jan 6;53(D1):D1683-D1691. doi: 10.1093/nar/gkae868.
3
Structural Modification Endows Small-Molecular SN38 Derivatives with Multifaceted Functions.结构修饰赋予小分子 SN38 衍生物多方面的功能。
Molecules. 2023 Jun 22;28(13):4931. doi: 10.3390/molecules28134931.
4
Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer.单一抑制剂与双重抑制剂：组蛋白去乙酰化酶在癌症中的作用
ACS Omega. 2023 May 1;8(19):16532-16544. doi: 10.1021/acsomega.3c00222. eCollection 2023 May 16.
5
Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors.癌症中的表观遗传调控：预测生物标志物和克服拓扑异构酶 I 抑制剂耐药性的潜在靶点。
Ann Med. 2023 Dec;55(1):2203946. doi: 10.1080/07853890.2023.2203946.
6
First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids.首例双重作用铁死亡-HDAC 抑制剂杂合体。
J Med Chem. 2022 Nov 10;65(21):14764-14791. doi: 10.1021/acs.jmedchem.2c01276. Epub 2022 Oct 28.
7
Research Advances on Anti-Cancer Natural Products.抗癌天然产物的研究进展
Front Oncol. 2022 May 6;12:866154. doi: 10.3389/fonc.2022.866154. eCollection 2022.
8
R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin.R 环介导的单链 DNA 断裂在短期暴露于组蛋白去乙酰化酶抑制剂罗米地辛后积累。
Mol Cancer Res. 2021 Aug;19(8):1361-1374. doi: 10.1158/1541-7786.MCR-20-0833. Epub 2021 May 28.
9
Application of Amino Acids in the Structural Modification of Natural Products: A Review.氨基酸在天然产物结构修饰中的应用：综述
Front Chem. 2021 Apr 29;9:650569. doi: 10.3389/fchem.2021.650569. eCollection 2021.
10
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.组蛋白去乙酰化酶抑制剂的抗癌治疗：基于机制的联合策略及未来展望
Cancers (Basel). 2021 Feb 5;13(4):634. doi: 10.3390/cancers13040634.
本文引用的文献
1
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.靶向癌症治疗：给予组蛋白去乙酰化酶抑制剂成功所需的一切。
Future Med Chem. 2012 Mar;4(4):505-24. doi: 10.4155/fmc.12.3.
2
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.新型双功能抑制剂双重靶向组蛋白去乙酰化酶和拓扑异构酶 II。
J Med Chem. 2012 Feb 23;55(4):1465-77. doi: 10.1021/jm200799p. Epub 2012 Feb 13.
3
Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.来源于三环酮内酯骨架的非肽类大环组蛋白去乙酰化酶抑制剂。
J Med Chem. 2010 Aug 26;53(16):6100-11. doi: 10.1021/jm100507q.
4
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.含三唑连接帽基团的组蛋白去乙酰化酶抑制剂的抗疟和抗利什曼原虫活性。
Bioorg Med Chem. 2010 Jan 1;18(1):415-25. doi: 10.1016/j.bmc.2009.10.042. Epub 2009 Oct 27.
5
Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines.喜树碱和阿拉伯茶（阿拉伯茶）诱导急性髓系白血病细胞系中涉及 c-FLIPL、Mcl-1、procaspase-8 和线粒体功能调节的不同细胞死亡表型。
Mol Cancer. 2009 Nov 13;8:101. doi: 10.1186/1476-4598-8-101.
6
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.ABT-869，一种有前途的多靶点酪氨酸激酶抑制剂：从实验室到临床。
J Hematol Oncol. 2009 Jul 30;2:33. doi: 10.1186/1756-8722-2-33.
7
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.DNA拓扑异构酶I抑制剂：化学、生物学及界面抑制
Chem Rev. 2009 Jul;109(7):2894-902. doi: 10.1021/cr900097c.
8
Non-peptide macrocyclic histone deacetylase inhibitors.非肽大环组蛋白脱乙酰酶抑制剂
J Med Chem. 2009 Jan 22;52(2):456-68. doi: 10.1021/jm801128g.
9
DNA cleavage assay for the identification of topoisomerase I inhibitors.用于鉴定拓扑异构酶I抑制剂的DNA切割试验
Nat Protoc. 2008;3(11):1736-50. doi: 10.1038/nprot.2008.174.
10
Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.含三唑连接帽基团的组蛋白去乙酰化酶（HDAC）抑制剂的合成及其构效关系
Bioorg Med Chem. 2008 May 1;16(9):4839-53. doi: 10.1016/j.bmc.2008.03.050. Epub 2008 Mar 23.
Zotero 插件